Hepatitis C virus (HCV) is an RNA virus with a high mutation rate, contributing to its ability to evade the host immune response and develop resistance to antiviral medications. The HCV life cycle involves viral entry, translation, replication, and assembly, making it a complex target for therapeutic intervention. Antiviral drugs targeting various stages of the HCV life cycle have been developed, with direct-acting antivirals (DAAs) being the latest breakthrough. However, the emergence of drug-resistant variants poses a challenge to the sustained effectiveness of antiviral therapy. Monitoring for drug resistance, understanding the mechanisms of resistance, and developing new antiviral agents are crucial aspects of managing hepatitis C. Future perspectives in hepatitis C research include the exploration of host-targeted therapies, immune-based approaches, and strategies for vaccine development. Host factors influencing HCV replication and the immune response are potential targets for therapeutic intervention. Efforts to develop an effective hepatitis C vaccine aim to provide long-term protection and contribute to global hepatitis C elimination goals. Research also focuses on understanding the dynamics of HCV transmission, particularly in high-risk populations, to inform targeted prevention strategies. Integration of hepatitis C care into broader healthcare systems and public health initiatives is essential for achieving sustained reductions in HCV prevalence and preventing new infections. In summary, ongoing research and advances in treatment modalities offer hope for improved outcomes in hepatitis C management. Combining effective antiviral therapy with comprehensive prevention strategies is crucial for achieving the ultimate goal of eliminating hepatitis C as a public health threat.